References
- Heslop CL, Frohlich JJ, Hill JS. Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography. J. Am. Coll. Cardiol.55(11), 1102–1109 (2010).
- Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J. Am. Coll. Cardiol.54(23), 2129–2138 (2009).
- Munzel T, Gori T. Lipoprotein-associated phospholipase A(2), a marker of vascular inflammation and systemic vulnerability. Eur. Heart J.30(23), 2829–2831 (2009).
- De Keyzer D, Karabina SA, Wei W et al. Increased PAFAH and oxidized lipids are associated with inflammation and atherosclerosis in hypercholesterolemic pigs. Arterioscler. Thromb. Vasc. Biol.29(12), 2041–2046 (2009).
- Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med.359(21), 2195–2207 (2008).
- Schindhelm RK, van der Zwan LP, Teerlink T, Scheffer PG. Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification? Clin. Chem.55(8), 1462–1470 (2009).
- Shishehbor MH, Aviles RJ, Brennan ML et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA289(13), 1675–1680 (2003).
- Mohiuddin I, Chai H, Lin PH et al. Nitrotyrosine and chlorotyrosine: clinical significance and biological functions in the vascular system. J. Surg. Res.133(2), 143–149 (2006).
- Stefanescu A, Braun S, Ndrepepa G et al. Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. Am. Heart J.155(2), 356–360 (2008).
- Ohman EM, Granger CB, Harrington RA, Lee KL. Risk stratification and therapeutic decision making in acute coronary syndromes. JAMA284(7), 876–878 (2000).